Transparent interactions

Working with healthcare professionals and patients

We are committed to transparency. Therefore, we disclose the transfers of value we make to individual healthcare professionals and patients and to their respective organizations. We work with healthcare professionals and patient organizations to deliver new treatment options within brain diseases and our interactions are well-regulated.

Strength in collaboration

To develop and deliver innovative treatment of brain disease, we work with a range of stakeholders. These include healthcare professionals, patients and their respective organizations. We collaborate on research, clinical development, exchange of scientific information, and marketing and sales activities.

 

These interactions are well-regulated by the national laws and industry association regulations that we integrate into our working processes, training and guidance.  

 

We are committed to transparency and our disclosed information follows the current laws or regulations from the industry associations we have joined, such as the European Federation of Pharmaceutical Industries and Associations (EFPIA).  

Dialogue with decision makers in Denmark

According to the Ethical rules for dialogue and negotiations with decision-makers published by Danish Ethical Committee for the Pharmaceutical Industry, every pharmaceutical company is obliged to publish a schedule on their website with the names of the PR or communication agencies, legal counsel or similar external consultancies acting on behalf of the pharmaceutical company to engage in dialogue and negotiations with decision-makers.

 

The following external consultants are representing H. Lundbeck A/S in dialogue and negotiation with decision makers:

 

Rud Pedersen Public Affairs
Christians Brygge 24, 3.
DK- 1559 København V

 

Lead Agency
Ravnsborg Tværggade 5c, 1.
DK-2200 København N

 

We have made the external agencies aware of the present set of rules and that the pharmaceutical company accepts responsibility for ensuring third party compliance therewith.

Transfers of value to healthcare professionals and patient organizations

Here you can find an overview, together with the locations, of Lundbeck’s interactions with healthcare professionals and the related transfers of value:   

Countries that disclose

Country       Year       Links
Austria   2020-2024   Lundbeck Austria Website
Belgium   2015-2024   Industry Association Website
Brazil   2017-2024   Industry Association Website
Bulgaria   2022-2024   Lundbeck Corporate Website
Croatia   2015-2024   Lundbeck Corporate Website
Cyprus   2015-2024   Lundbeck Greece Website
KEFEA
Czech Republic   2015-2024   Industry Association Website
Denmark   2017-2025   Local Authority Website
PO Sponsorships
Estonia   2022-2024   Lundbeck Estonia Website
Finland   2022-2024   Lundbeck Finland Website
France   2019-2024   The Ministry of Health and Access to Care
Website
Germany   2021-2024   Lundbeck Germany Website
Greece   2015-2024   Lundbeck Greece Website
Hungary   2020-2024   Lundbeck Corporate Website
Ireland   2021-2024
2019-2024
  Industry Association Website
PO Sponsorships
Italy   2016-2024   Lundbeck Italy Website
Japan   2015-2024   Lundbeck Japan Website
Latvia   2017-2024   Health Inspectorate
Lithuania   2022-2024   Health Inspectorate
Luxembourg   2015-2024   Industry Association Website
Norway   2022-2024   Lundbeck Norway Website
Poland   2022-2024   Lundbeck Poland Website
PO sponsorships
Portugal   2013-2024   Health Authority Website
Romania   2016-2024   Local Authority Website
Russia   2015-2024   Lundbeck Russia Website
Slovakia   2015-2024   Lundbeck Slovakia Website
Industry Association Website
Slovenia   2022-2024   Lundbeck Slovenia Website
Spain   2021-2024   Lundbeck Spain Website
Sweden   2022-2024   Industry Association Website
Switzerland   2021-2024   Lundbeck Switzerland Website
The Netherlands   2021-2024   Industry Association Website
Ukraine   2020-2024   Lundbeck Corporate Website
United Kingdom   2015-2024   Industry Association Website
PO Sponsorships
United States   2016-2024   Federal Government Website

Aggregate disclosures

Lundbeck discloses payments and other transfers for value to HCPs and HCOs in aggregate, if the HCP or HCO has used their legal right to refuse consent to individual disclosure, in accordance with the EFPIA Disclosure Code. The data covers Lundbeck affiliates that use Lundbeck’s corporate website for disclosure. Data from other countries can be found on the Country overview tab.

Historic research and development disclosures

Lundbeck undertakes research activities and conducts clinical studies globally. Clinical studies are conducted in accordance with international guidelines and performed by HCPs and HCOs. Our payments and other transfers of value related to pre-clinical, clinical and non-interventional studies are disclosed in aggregate.

R&D payments to HCPs & HCOs
 
Country 2020 2021
     
Bulgaria €745,539 €403,565
Croatia €5,101 -
Estonia -
-
Hungary €52,343 €46,635
Latvia -
-
Lithuania -
-
Ukraine €413,939 €232,245

The amounts cover payments and other transfers of value to HCPs and HCOs related to pre-clinical, clinical and non-interventional studies in the countries where the Lundbeck affiliate uses Lundbeck’s corporate website for disclosure in accordance with the EFPIA Disclosure Code.

 

Data from other countries can be found under countries that disclose.

More from Lundbeck